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Hepatocellular carcinoma (HCC) is the third most common cause of cancer deaths worldwide, and 
the incidence of this fatal disease is still on a rise. The majority of HCC emerge in the background of a 
chronic liver disease, such as chronic hepatitis and liver cirrhosis. The current understanding is that 
majority of HCCs evolve as a consequence of chronic inflammation and due to the presence of infection 
with hepatitis viruses. These underlying pathogenic stimuli subsequently induce a spectrum of genetic 
and epigenetic alterations in several cancer-related genes, which are involved in cell-cycle regulation, cell 
growth and adhesion. Such widespread genomic alterations cause disruption of normal cellular signaling 
and finally lead to the acquisition of a malignant phenotype in HCC. In general, the type of gene 
alterations, such as point mutations, deletion of chromosomal regions and abnormal methylation of gene 
promoters differ according to the individual targeted gene. In HCC, incidence of genetic alterations is 
relatively rare and is limited to a subset of few cancer-specific genes, such as the tumor suppressor p53, 
RB genes and oncogenes such as the CTNNB1. In contrast, epigenetic changes that involve aberrant 
methylation of genes and other post-transcriptional histone modifications occurs far more frequently, and 
some of these epigenetic alterations are now being exploited for the development of molecular diagnostic 
signatures for HCC. In addition, recent findings of unique microRNA expression profiles also provide 
evidence for the existence of novel mechanisms for gene expression regulation in HCC. In this review 
article, we will review the current state of knowledge on the activation of various oncogenic pathways 
and the inactivation of tumor suppressor pathways in HCC that result in the disruption of cancer-related 
gene function. In addition, we will specifically emphasize the clinical implication of some of these 
genetic and epigenetic alterations in the management of hepatocarcinogenesis. 
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INTRODUCTION 
It is now widely accepted that stepwise accumulation of mutations in cancer-related genes and 
chromosomal alterations are involved in human carcinogenesis [1]. However, in the last decade we have 
recognized that in addition to genetic artifacts, epigenetic alterations that involve aberrant methylation of 
gene promoters and dysregulated expression of microRNA (miRNA), constitute equally important 
mechanisms of genomic instability in human cancers. Studies of these molecular alterations in 
hepatocellular carcinoma (HCC) has also revealed that this malignancy involves a multipathway process, 
and accumulation of genetic and epigenetic event leads to abnormal activation or inactivation of multiple 
cellular signaling pathways including cellular proliferation, cellular survival, differentiation, and 
angiogenesis. Additionally, the emerging consensus is that the core biological processes including 
regulation of p53/ARF, RB/INK4A and Wnt/-catenin pathways are commonly affected in a majority of 
HCCs regardless of the etiologies, suggesting the presence of a common oncogenic process of HCC 
development.  
This review provides an overview of genetic and epigenetic alterations observed in HCC, and 
discusses how these abnormalities relate to the disruption of specific biological signaling for the 
maintenance of homeostasis in normal hepatocytes. It is anticipated that such precise analyses of genomic 
profiling will reveal a global scheme of molecular classification of HCC, aid in the development of novel 
molecular-targeted therapy for specific subclasses of HCC, as well as assist in the discovery and 
development of diagnostic and predictive biomarkers of HCC. 
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P53/ARF PATHWAY 
The p53/ARF pathway plays a key role in a variety of cellular functions, such as regulation of cell 
cycle, apoptosis and DNA repair. Cellular stress activates this pathway by activating the p53 protein as a 
transcription factor, and leads to the induction of the transcriptional network of p53-responsive genes [2]. 
The p53 circuit communicates with several fundamental cellular signals, such as the Wnt/-catenin, 
RB/INK4a and p38 MAP pathways. Because the p53 protein has a variety of important functions for the 
maintenance of cellular responses, disruption of the p53/ARF pathway has been reported in almost every 
type of cancer including hepatocellular carcinoma (HCC) [3]. Notwithstanding the existence of multiple 
auto-regulatory loops that control p53 activity, MDM2 protein plays a central role in this process. The 
ARF antagonizes functions of MDM2 to induce regulatory responses that depend on the activation of p53 
and its target genes. Although disruption of the p53 occurs in a subset of HCC, more than half of tumors 
retain a wild-type p53, suggesting that alteration of other molecules involved in this pathway might also 
contribute to hepatocarcinogenesis [4]. 
 
1. The p53 gene 
The p53 gene is located on 17p13.1 and encodes this transcription factor with a tumor suppressor 
function. In human HCC, common alterations of the p53 gene are point mutations within the conserved 
region of exons accompanied by loss of the short arm of chromosome 17. Generally, 30 - 60% of HCC 
carry mutations of the p53 gene [3]. The spectrum of point mutations reported in HCC varies according to 
the etiology of the underlying molecular pathogenesis. For example, aflatoxin B1 (AFB1) reportedly 
induces G:C to T:A transversion mutation in codon 249 of the p53 [5, 6]. As this type of mutation is 
detected in serum of HCC patients with exposure to AFB1, this can be applied for risk assessment of 
HCC, and as a potential biomarker of HCC emergence and exposure to AFB1 [7]. However, it has been 
shown that AFB1-related liver tumor in rats didn’t carry specific mutations that corresponded to codon 
249 of human HCC [8]. On the other hand, transgenic mice with the hepatitis B virus-X (HBx) gene, in 
concert with AFB1 intake, develop HCC harboring G:C to T:A transversion mutation at the site 
corresponding to the codon 249 of the human p53 [9]. This evidence highlights the potential scenario 
where both AFB1 insult and infection with HBV are required for the evolution of specific mutations 
within the p53 gene in HCC. 
 
On the other hand, even though the mutational spectrum of the p53 gene in AFB1-negative HCC is 
heterogeneous, the majority of mutations are still confined to a conserved region of DNA-binding domain 
encoded on exons 5 – 9 [4].  
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Other reports suggest that viral proteins affect the function of the p53 protein and contribute to HCC 
formation. For example, HBx protein itself reportedly binds to p53 and disturbs its capacity for DNA 
binding, transcription and induction of apoptosis [10]. None of the previous reports have provided 
evidence for the direct action of HCV-related protein to p53. However, it has been shown that, nitric 
oxide (NO), which is induced by inflammatory cytokines such as TNF- and IFN- in chronic hepatitis C 
virus (HCV) infection, can induce mutation of cancer-related genes including the p53. In cases of colon 
cancer and lung cancer, nitric oxide synthetase 2 activity in the tumor closely related to the G:C to A:T 
mutations in the p53 gene within the CpG sites [11], which is the major type of mutation in the p53 gene 
found in HCC without AFB1 contamination.  
 
2. The CDKN2A (p14ARF) gene 
The CDKN2A gene encodes two tumor suppressors, p14ARF and p16INK4a, which share the same 
second exons. The p14ARF transcript functions as a stabilizer of the p53 protein. The p14ARF interacts with 
the MDM2 protein, which is responsible for the degradation of p53 and in regulating the control of cell 
cycle during G1-S phase [12]. This gene is frequently mutated or deleted in a wide variety of human 
tumors including HCC. Generally, 7% of HCC carry homozygous deletion of the CDKN2A gene, and 
inactivation of the p14ARF gene via aberrant methylation its gene promoter is a frequent event in HCC 
[13]. However, according to our analysis, methylation of the promoter of p14ARF was also evident in small 
proportion of non-cancerous liver tissues as well, but it was far more frequent in HCC tissues [14]. In 
addition, a decrease of mRNA level was detected exclusively in HCC with homozygous deletion of this 
gene. From this point of view, the role of methylation at the promoter of p14ARF may still be viewed 
somewhat controversial in pathogenesis of HCC [14]. 
 
3. The CDKN1A and CDKA1B genes 
Although alterations in the genomic sequences of the tumor suppressor CDKN1A and CDKN1B genes 
are rare in HCC, the down-regulation of these cell-cycle regulatory proteins has been frequently reported 
[15-17]. Expression of p21WAF1, the product of the CDKN1A gene, is regulated by the tumor suppressor 
p53, and p21WAF1 in turn regulates the activities of cyclin-dependent kinase (CDK) 2 and 4, which control 
the G1-S and G2-M phase of cell cycle, respectively. In human HCC, down-regulation of p21WAF1 has 
been observed and associates with tumor progression and bad prognosis of the disease [15]. The 




P27kip1, the product of the CDKN1B gene, is also a member of cyclin dependent kinase inhibitors 
(CDKI) and inhibits kinase activity of cyclin E-CDK2 and cyclin D-CDK4. The expression level of this 
CDKI was also correlated to the poorer outcomes for disease-free survival of HCC cases [17]. The 
protein level of p27kip1 was reportedly lower in cirrhotic liver of non-cancerous tissues of HCC cases than 
in those without HCC, and the down-regulation of its expression was associated with promoter 
methylation of the CDKN1B gene [17, 18]. 
  
RB/INK4A PATHWAY 
The RB/INK4A pathway plays a central role in the regulation of the G1-S phase of cell cycle 
progression. It is known that RB activities associate with its phosphorylation status, and phosphorylation 
of RB depends on cell cycle progression coupled with activation of CDK. The unphosphlyrated RB binds 
to the E2F-1 transcription factor, preventing it from interacting with the transcriptional machinery within 
the cell. The phosphorylated RB sequesters E2Fs, which are responsible for the transcription of many 
genes [19]. Among these genes, cyclin E, which binds to the CDK2, induces DNA replication during cell 
cycle. The majority of tumors, including HCC, frequently harbor aberrations of the members of this 
pathway. Our analyses indicate that 81% of HCC showed alteration of at least one component of the 
RB/INK4A pathway [20-22].  
 
1. The RB gene 
Loss of RB activity has been identified in many types of cancers including retinoblastoma, 
osteosarcomas, small cell and non-small cell lung cancers, breast cancer and HCC. In human HCC, 18 – 
48% of tumors represent chromosomal loss of 13q14 region, where the RB gene resides. Our previous 
reports demonstrate that some HCCs with loss of heterozygosity on 13q14 carry additional structural 
alterations of the interstitial deletion in the RB gene, suggesting that a double hit on this locus leads to 
complete functional inactivation of RB [23]. On the other hand, down-regulation of RB protein is 
observed in 30-50% of HCC tissues compared to their corresponding non-neoplastic liver tissues [24]. 
Although the precise mechanism of the down-regulation of RB has not been clarified completely, some 
reports have suggested that abnormal methylation of the RB promoter may cause transcriptional 
inactivation of the gene in cancer cells [25]. 
 
2. CDKN2A (p16INK4a ) gene 
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As described previously, p16INK4a is a tumor suppressor protein, which is encoded by the CDKN2A 
gene. This molecule plays an important role in regulating the cell cycle, by inhibiting CDK4 and 
controlling cell cycle progression at the G1 phase. Mutation of p16INK4a is also involved in the 
development of a variety of cancers including HCC.  
 Some HCCs carry homozygous deletions or point mutations of p16INK4a [26]. However, recent data 
suggest that the major mechanism of inactivation of this gene is abnormal methylation of its gene 
promoter. As much as 40-70% of HCCs demonstrate p16INK4a methylation, and this aberrant methylation 
associates with down-regulation of the protein expression [27]. Since low-levels of methylation were also 
detected in the background non-cancerous liver of the HCC patients, we normalized methylation levels in 
HCC tissues to the background aberrant methylation and determined that p16INK4a methylation inactivates 
the gene in 63% of human HCC cases (Fig. 1) [28]. Previous reports suggest that p16INK4a methylation 
also associates with the presence of HBV or HCV infection [29].  
 As described above, there is a close association between RB/INK4A pathway and p53/ARF pathway, 
especially in the regulation of cell cycle progression and apoptosis. We summarized the association of the 
responsible molecules in these pathways and the type of their alterations found in HCC in Fig. 2. 
 
WNT/-CATENIN PATHWAY 
Activation of Wnt/-catenin pathway facilitates the expression of several genes indispensable for cell 
growth, such as c-myc and cyclin D1, through translocation of -catenin to nucleus and its interaction 
with various transcription factors.  
In general, -catenin within cells is present in the form of complexes with several proteins, and the 
ability of -catenin to bind to other proteins is regulated by tyrosine kinases and serine kinases, such as 
glycogen synthase kinase (GSK)-3. The binding proteins include cell adhesion molecules, several 
transcription factors, and axin, which is a component of the Wnt signalling pathway. -catenin is 
associated with axin complex together with GSK-3 and APC (adenomatosis polyposis coli) [30, 31]. 
This complex substantially induces the increase in phosphorylation of -catenin by facilitating the action 
of GSK-3 which leads to ubiquitin-dependent degradation of -catenin by proteosomes. The action of 
GSK-3 is inhibited by the binding of Wnt to its receptors, which leads to the translocation of -catenin 
to the nucleus and induction of a variety of functions within this pathway [32]. -catenin also acts in 
conjunction with T-cell factor (TCF)/lymphoid enhancing factor (LEF) family transcription factors to 
activate several target genes.  
Among the components of the Wnt/-catenin pathway, the APC gene is known to be the primary 
target in patients with familial adenomatous polyposis (FAP) colon cancers [33]. Similarly, mutation of 
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the AXIN2 is a cause of attenuated polyposis [34], and mutation of the CDH1 gene is known to induce 
familial gastric cancer [35]. Alterations of several components of this pathway is also a common event in 
human HCC (Fig. 3). 
 
1. The CTNNB1 gene 
-catenin is encoded by the CTNNB1 gene and plays an important role in various aspects of liver 
biology including pathogenesis of liver cancer. Mutations in this gene are the cause of several cancers, 
such as colorectal cancer and ovarian cancer [36, 37]. In human HCC, point mutations or deletions at the 
phosphorylation site on neighboring codons in the exon 3 of the CTNNB1 have been proposed to cause 
deregulation of the signaling function and contribute towards HCC pathogenesis. Generally speaking, 
10–30 % of HCC carry mutations of the CTNNB1 gene, which induces the accumulation of -catenin in 
the nucleus [28].  
 
2. The AXIN genes 
As described above, axin protein interacts with APC, -catenin, GSK-3, and protein phosphate 2. 
Mutations in this gene are also associated with hepatocellular carcinoma, hepatoblastomas, and several 
other cancers. Mutations of the AXIN1 gene can be detected in 5–9 %, and mutations of the AXIN2 are 
reported in ~3% of human HCC or HCC cell lines that carry the wild type CTNNB1 gene [38]. Gene 
transfer of wild-type AXIN1 resulted in enhanced apoptosis in HCC cell lines as a consequence of 
increased accumulation of -catenin in the nucleus. On the other hand, some target genes of -catenin, 
such as glutamine synthetase, did not show enhanced expression even in cell lines with the mutated AXIN 
genes, suggesting that the tumor suppressor function of this protein might act via additional pathways 
other than Wnt/-catenin [39]. 
 
3. The APC gene 
APC also forms complexes with axin and GSK-3and contributes in controlling cellular -catenin 
levels through ubiquitin proteasome-dependent degradation of -catenin. In human HCC, biallelic 
inactivation of the APC gene (mutation of the gene accompanied by loss of chromosomal region of the 
APC locus) was reported in a HCC case [40]. In our analysis, 84% of HCC carried dense methylation on 
the promoter of this gene in HCC (Fig. 1), indicating that promoter methylation was the major mechanism 
of inactivation of the APC gene in human HCC . 
 
4. The CDH1 (E-cadherin) gene 
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E-cadherin is a calcium-dependent cell-cell adhesion glycoprotein that plays an important role in the 
formation of the epithelial cell layer. Cadherin can be found in complexes with catenin, which is 
important for the biological function of this gene. The oncogenic signals from EGF and Src also target 
-catenin. It has been shown that phosphorylation of -catenin through the EGF pathway associated with 
invasion and metastasis of cancer because of suppression of the adhesion function of cadherin [41]. 
Mutations of this gene are reported in gastric, colorectal, and breast cancers. Loss of function of this gene 
contributes to the progression of HCC by permitting increased proliferation, invasion, and metastasis of 
the neoplastic cells. Expression analysis of E-cadherin in hepatocellular carcinomas demonstrated that 
56% of HCC showed down-regulation of E-cadherin expression, and this phenomenon directly correlated 
with the size of tumors, as well as the mitotic index and survival [42].  
 
Several reports suggested that the CDH1 gene can also be inactivated through the promoter 
hypermethylation of its promoter region. Interestingly, it has also been reported that reactive oxygen 
species (ROS) induce hypermethylation of the CDH1promoter. In this context, activation of 
PI3K/Akt/GSK-3 by ROS has been shown to recruitment of histone deacethylase and DNA 
methyltransferase on its promoter, which causes the downregulation of CDH1expression [43]. Because 
longstanding chronic inflammation enhances the production of ROS in the background liver of HCC, it is 
reasonable to speculate that these epimutations play an important role in the initial steps of 
inflammation-related hepatocarcinogenesis. 
 
5. Secreted frizzled-related protein (SFRP) 2  
Frizzled are membrane proteins which are known as receptors of Wnt. SFRPs act as soluble 
modulators of Wnt signaling as SFRPs containing the putative Wnt-binding site of frizzled proteins. 
Because SFRPs are able to down-regulate Wnt signaling by forming an inhibitory complex with the 
frizzled receptors, SFRPs are considered as tumor suppressors. We have reported that one of the SFRP 
family genes, SFRP2, showed hypermethylation of its promoter and was frequently inactivated in human 
HCC (Fig. 1) [28]. 
 
ABNORMAL METHYLATION OF TUMOR SUPPRESSOR GENES 
It is now increasingly being recognized that the patterns of DNA methylation, which are ordinarily 
maintained during normal cell division, are often disturbed in many human tumors, including HCC. Since 
low levels of DNA methylation can also be detected in the non-cancerous liver in patients with chronic 
liver damage or HCC, it is now believed that this epigenetic defect emerges at an early stage during 
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hepatocarcinogenesis [44]. In human HCC, both regional hypermethylation of tumor suppressor gene 
(TSG) promoters and hypomethylation of repetitive DNA sequences are commonly observed [45]. The 
former is an important mechanism for the inactivation of corresponding gene, while the latter plays a role 
in maintaining chromosomal fragility and activation of retrotransposons and microRNA (miRNA), both 
of which could be critical for HCC development and progression. Although the precise mechanisms for 
the alteration of DNA methylation during hepatocarcinogenesis are still unclear, both HBx and HCV core 
proteins have been shown to induce the expression of DNA methyltransferases, which then leads to 
abnormal methylation of the CDH1 gene [46, 47].  
 
We have previously reported that DNA methylation of TSGs was closely associated with the 
presence of HCV not only in HCCs but also in chronic hepatitis tissues, suggesting that the chronic 
inflammation or presence of HCV may contribute to the emergence of abnormal methylation [48]. The 
numbers and frequencies of genetic alterations of cancer-related genes in HCC are limited, however, 
epigenetic alterations are frequently observed in several TSGs (Fig. 1) [49]. 
 
CLINICAL IMPLICATIONS OF GENETIC AND EPIGENETIC ALTERATIONS 
Cancer specific alterations of several genes are promising candidates for developing molecular 
markers of HCC, such as diagnosis and prediction of prognosis. Among them, alteration of DNA 
methylation is widely and frequently observed in almost every HCC, and DNA methylation can be easily 
and quantitatively measured in a variety of clinical specimens. Detection of methylation of the CDKN2A 
and GSTP1 genes in serum has been used for the early diagnosis of HCC [50, 51]. Furthermore, detection 
of the methylated CDKN2A and RASSF1A genes in serum of cases at high risk of HCC could predict 
early occurrence of HCC [52]. Similarly, alteration of certain cancer-related genes or oncogenic pathways 
could be a target of developing a novel therapy of HCC. For example, a high level of copy-number gain 
and overexpression of vascular endothelial growth factor A was reported in a subset of HCC, suggesting 
that antiangiogenic therapies could be exclusively effective for this type of tumor [53]. 
 
ALTERED EXPRESSION OF miRNAs 
Expression of miRNAs, which have been identified as a new class of small non-coding family of 
genes that are involved in post-transcriptional gene regulation, is also shown to be frequently altered in 
HCC. Several comprehensive analyses of miRNA have identified differentially expressed miRNAs in 
various subsets of HCCs. This type of alteration can also modulate several important signaling pathways, 
which is critical for hepatocarcinogenesis.  
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In human HCCs, miRNA (miR)-122 expression is significantly reduced in a subset of HCC 
compared to the non-cancerous tissues [54]. miR-122 can modulate cyclin G1 expression in HCC-derived 
cell lines, and an inverse correlation between miR-122 and cyclin G1 expression has been shown in 
human HCC, suggesting that cyclin G1 is a target of miR-122 [55]. On the other hand, miR-221 also 
targets cell-cycle inhibitors CDKN1B (p27kip1) and CDKN1C (p57kip2) and its altered expression also 
results in disturbed normal cell-cycle regulation in hepatocytes [56].  
MiR-21 is shown to be overexpressed in HCC as well as HCC cell lines, and inhibition of miR-21 
increases expression of the tumor suppressor PTEN which helps in decreased tumor proliferation and 
invasion [57]. On the other hand, Ji, et al showed that tumors with reduced miR-26 expression had a 
distinct transcriptomic pattern, with the activation of NF-B and IL-6 signaling pathways [58]. 
Interestingly, induction of IL-6 is reported as an important step for inflammation-related HCC 
pathogenesis [59], and high levels of serum IL-6 can be a risk factor for HCC in HCV-positive patients 
[60]. Activation of this pathway also accounts for the gender differences and risk of HCC, as estrogen is 
known to suppress MyD88-dependent IL-6 production, and miR-26 is expressed at higher level in women 
than men in the liver [58, 59]. Reportedly, this miRNA is also a good candidate for therapeutic target of 
HCC. Patients whose tumors had low miR-26 expression had shorter survival but a better response to 
interferon therapy than did patients whose tumors had high expression of this miRNA [58]. In addition, 
Kota, et al reported the significance of this miRNA on treatment response using a mouse model [61]. 
Expression of miR-26 in liver cancer cells in vitro induces cell cycle arrest via suppression of cyclin D2 
and cyclin E2, and systemic administration of miR-26 in mouse HCC model induces inhibition of cancer 
cell proliferation and induction of tumor-specific apoptosis without toxicity [61]. However, as individual 
miRNAs regulate hundreds of transcripts, antiproliferative effects of miR-26 in HCC, might not attribute 
to a single oncogeneic pathway but a regulation of multiple pathways, such as c-Myc and p53-dependent 
pathway. 
On the other hand, several other studies revealed the association between expression profile of 
miRNA and etiology as well as specific genetic alterations. The miR-96 is overexpressed in HBV-related 
tumors, and miR-126 is down-regulated in alcohol-related hepatocellular carcinoma. Similarly, several 
reports suggest that the expression profile of miRNA can be applied to evaluate the etiology of tumor and 
predict tumor behavior, such as metastasis and prognosis [58, 62-66]. These evidences support the idea 
that in addition to genetic and epigenetic alteration of oncogenes and TSGs, altered expression of 
miRNAs is an additional mechanism critical for human hepatocarcinogenesis. This concept is bound to 
receive a lot of attention in the coming years, as it not only helps in a better understanding of the 
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molecular mechanisms of HCC, but also has a potential for clinical use including the development of 
biomarkers and therapeutic targets of this malignancy.  
 
CONCLUSION 
We have summarized in this review article the spectrum of various genetic and epigenetic alterations 
in a variety of genes and their corresponding oncogeneic pathways that are operational in human 
hepatocarcinogenesis (Fig. 2, Fig. 3). What we now understand is that similar to many other cancers, 
development of HCC associates with a step-wise accumulation of genetic and epigenetic defects in 
cancer-related genes that includes point mutations, chromosomal alterations, aberrant DNA methylation 
and alterations of miRNA expression. Although the precise underpinnings of these various processes are 
still hazy, nonetheless, it is very likely that the defects in multiple signaling pathways might overlap and 
crosstalk exists among these pathways, as the premalignant clones progress towards a more advanced 
stage of HCC. Given the high prevalence of chronic liver disease and HCC patients, knowledge of these 
molecular events is very exciting and timely, because an understanding of these events will help tailor 
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Mean methylation levels and frequencies of hypermethylation of several tumor suppressor genes 
(TSGs) in HCC. In contrast to genetic alterations such as point mutation, a variety of TSGs are frequently 
inactivated via epigenetic mechanism, suggesting that DNA methylation is a major alteration as a driver 
for human hepatocarcinogenesis.  
 
Fig. 2 
Schematic representation of alterations in p53/ARF and RB/INK4A pathways in HCC.  
Molecules with oncogenic function are shown in yellow and those with tumor suppressive function 




Schematic representation of Wnt/-catenin pathway and the alterations reported in HCC. 
Functions of molecules shown in yellow and blue represent oncogenic and tumor suppressive 
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